Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEV-296
- Development stage
- Preclinical
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TEV-296 is a biosimilar monoclonal antibody candidate being developed by Teva Pharmaceuticals. It is designed to be biosimilar to **pembrolizumab** (marketed as Keytruda), a blockbuster immune checkpoint inhibitor. TEV-296 targets the **programmed cell death protein 1 (PD-1)** receptor on T cells. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), the drug prevents the downregulation of the immune system, thereby enhancing the body's ability to recognize and attack cancer cells. As of 2024, TEV-296 is in the preclinical stage of development, with the goal of providing a more affordable alternative for the various oncological indications currently treated by the reference product.
- Other names
- pembrolizumab biosimilar
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on TEV-296.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TEV-296.